Skip to content
Free U.S. Standard shipping · Free international Standard shipping over US$150. Free U.S. shipping · International free over US$150.
Take the assessment

Explore HealthspanX

Secondary human analysis

Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration

Ajla Hodzic Kuerec, Weilan Wang, Lin Yi, Rongsheng Tao, Zhigang Lin, Aditi Vaidya, Sohal Pendse, Sornaraja Thasma, Niranjan Andhalkar, Ganesh Avhad, Vidyadhar Kumbhar, Andrea B. Maier

Mechanisms of Ageing and Development · 2024 · 218:111917

Original publication PubMed

Study at a glance

Design
Post-hoc analysis of the randomized double-blind 80-person Yi et al. NMN dose-ranging trial
Population or model
Generally healthy adults aged 40–65 years from the parent trial
Sample size
80 participants from the parent trial
Intervention
Parent trial: placebo or NMN 300, 600, or 900 mg/day for 60 days
Publication type
Post-hoc clinical-trial analysis
Evidence class
human-study
Research area
NAD response variability
Trial registration
Parent trial: NCT04823260; CTRI/2021/03/032421

Study endpoints

  • Change in blood NAD concentration
  • Interindividual variability in NAD response
  • Associations between NAD change and six-minute walk distance
  • Associations between NAD change and SF-36

Plain-language summary

This paper re-analyzed the 80-person Yi et al. randomized trial to examine how strongly individuals differed in their blood NAD response to 300, 600 or 900 mg/day NMN.

The analysis reported a dose-related average increase in NAD but also very large person-to-person variability. Larger increases in NAD were statistically associated with improvements in six-minute walk distance and SF-36 scores.

These are post-hoc associations from the same trial population, not a new randomized comparison. They can generate hypotheses about response variability but cannot prove that targeting a particular NAD level causes better clinical outcomes.

Key findings

  • Blood NAD response increased with dose on average.
  • Within-group variability in NAD response was large.
  • Greater NAD changes were associated with six-minute walk and SF-36 changes.
  • The paper proposed monitoring NAD as a possible basis for personalized dosing.
  • All data came from the previously published Yi et al. trial rather than a new participant cohort.

Limitations

  • Post-hoc secondary analysis.
  • Not an independent clinical trial or new sample.
  • Associations between NAD change and functional outcomes do not establish causality.
  • Commercial sponsorship and affiliations from the parent study remain relevant.
  • Proposed personalized dosing thresholds require prospective validation.

Funding and transparency

Funding

This is a post-hoc analysis of the commercially funded Yi et al. dose-ranging trial.

Competing interests

Lin Yi was affiliated with Abinopharm; the parent trial had commercial sponsorship and company-affiliated authors.

HealthspanX observation

This record must not be counted as an independent trial because it re-analyzes the Yi 2023 cohort.

Interpretive weight

Limited

Useful secondary analysis of interindividual NAD response, but not an independent trial and associations with functional outcomes are post hoc.

This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.

Your cart (0)

Your cart is empty.

Explore Ultra Pure NMN, read the label and choose your pack when you’re ready.

Explore Ultra Pure NMNExplore the journal
HealthspanX

What are you looking for?

Useful starting points